Cosentyx price uk. 3 The list price of secukinumab is £609. Solution f...
Cosentyx price uk. 3 The list price of secukinumab is £609. Solution for injection All products Excipients May contain polysorbates. SMC2592 secukinumab 150 mg or 300 mg solution for injection in pre-filled pen or pre-filled syringe (Cosentyx®) Novartis Pharmaceuticals UK Ltd Cosentyx (also referred to by its generic name, Secukinumab) is a biologic medication approved to treat severe psoriasis and psoriatic arthritis under certain circumstances in England, Wales and Scotland. Learn about cost, financial and insurance assistance, and more. Jan 24, 2026 · Patients and insurers commonly query the monthly cost of Cosentyx. Good luck to you on this project. I suppose the cost of Cosentyx could be different in the UK, but in a 'cash transaction without insurance' I doubt it would be much different. 03 a month for either a 150-mg or a 300-mg dose strength self-injection package and $4,489. Cosentyx (secukinumab) is indicated for the treatment of adults with: Moderate to severe plaque psoriasis. § The list price may not reflect the price paid by patients; most patients with prescription coverage will pay less. Pharmaceutical company Novartis Pharmaceuticals UK Ltd BNF chapter Musculoskeletal and joint diseases, Skin Submission type Full Status Restricted Date advice . The exact price depends on dosage, coverage, and pharmacy factors, but the sections below provide clear low, average, and high estimates and the main cost drivers. Apr 16, 2025 · Cosentyx is a prescription drug used to treat psoriasis and other conditions. Indication under review: treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging evidence in adults who have responded inadequately to non steroidal anti Medicine details Medicine name: secukinumab (Cosentyx) SMC ID: 1054/15 Indication: treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Patient leaflet - Cosentyx 1. 78 per 300 mg/2 ml solution for injection pre Oct 16, 2016 · The will translate into $16,258 for the 1st month and $4065 per month thereafter. 34 per intravenous infusion. Learn more about COSENTYX® (secukinumab), a treatment option for PsO, HS, PsA, AS, nr-axSpA, pediatric PsO, and pediatric JIA. Dec 18, 2025 · Cosentyx is a medicine that acts on the immune system (the body’s natural defences) and is used to treat the following conditions: moderate to severe plaque psoriasis (a disease causing red, scaly patches on the skin) in adults and children above 6 years old who need treatment with a systemic medicine (a medicine given by mouth or by injection); View secukinumab information, including dose, uses, side-effects, pregnancy, breast feeding, contra-indications, directions for administration and drug action. See full prescribing and safety information. Secukinumab is a monoclonal antibody which belongs to a group of medicines called interleukin (IL) inhibitors. We would like to show you a description here but the site won’t allow us. Please contact us to verify price and Oct 7, 2021 · 2. This article outlines typical cost ranges, how pricing is determined, and ways to estimate a month-to-month budget. What Cosentyx is and what it is used for Cosentyx contains the active substance secukinumab. Dec 6, 2023 · Secukinumab (Cosentyx, Novartis) is indicated for the treatment of 'active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic HS therapy'. The list price of secukinumab is £1,218. Active psoriatic arthritis (PsA). Show all solution for injection products (4) Show Cosentyx 150mg/1ml solution for injection pre-filled pens Novartis Pharmaceuticals UK Ltd Aug 19, 2025 · Cosentyx 150 mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC) by Novartis Pharmaceuticals UK Ltd Jul 21, 2021 · Secukinumab (Cosentyx, Novartis) is 'indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) in adults who have responded inadequately to non-steroidal anti-inflammatory drugs (NSAIDs)'. gafufq zvmzi ltzj qplmuh xyw hbgxw vtttnw ufnoq mpalwt efar
